You can keep up to date with the SINAPPS study by following
@sinapps_group on twitter
or visiting facebook.com/SINAPPSgroup/
A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis
Psychosis and schizophrenia are caused by genetic and environmental factors. Additionally there is increasing evidence of the role of antibodies in causing symptoms of psychosis and schizophrenia.
The hypothesis underlying the SINAPPS 2 trial is that these antibodies are pathogenic and may be responsible for isolated psychosis.
We launched this study to test if immunotherapy can be an effective treatment for antibody-associated psychosis.
The treatment will consist of two medications: IVIG and Rituximab. IVIG has been used in NMDAR encephalitis extensively and is effective and safe in other antibody-associated disorders.
Rituximab has also been used in NMDAR encephalitis, VGKC-antibody-associated psychosis, and other immunological disorders with good effect and a good safety profile.
Recruitment began in July 2017 and the study will run until December 2021.
This trial is funded by the Medical Research Council.
SINAPPS2 is an ongoing study involving participants from all across England. It will test the efficacy and safety of immunotherapy (IVIG and Rituximab) in people suffering from psychosis and positive to pathogenic antibodies
If you want to know more about the study procedures and the eligibilty criteria, click here
You can keep up to date with the SINAPPS2 study by following us on social media